UCLA Health reviewed 6 peptides: the evidence

UCLA Health’s September 2, 2026 Q&A with the authors of its new review of six popular peptide supplements is bluntly titled “With peptide supplements, marketing outpaces the medicine.”[1] The underlying review — “Peptide Supplements and Their Therapeutic Applications in Sports Medicine,” online in The American Journal of Sports Medicine since Aug 11, 2026 — found little evidence of benefit and “potentially concerning safety issues.”[1][2][3] “It’s a lot of marketing and very little substance,” said Dr. Thomas J. Kremen Jr., a UCLA sports medicine specialist and review co-author. “The evidence that these peptides are effective is just not there.”[1]

Here’s the review’s evidence, peptide by peptide. (For the marketing side, see what the ads don’t tell you.)

What UCLA Health actually reviewed

The UCLA orthopaedic team — including Kremen and medical student Kushagra Tewari — reviewed the literature on six peptides marketed for musculoskeletal recovery, tissue repair and performance: BPC-157, TB-500 (thymosin beta-4), CJC-1295, MK-677 (ibutamoren), ipamorelin and GHK-Cu (copper peptide). The team says it analyzed 565 studies in animal or human models.[1][2]

More than two-thirds were animal studies, most commonly in rats. Kremen: “More than two-thirds of these studies were only done in animals. We found they had some promising but variable effects on tendon, muscle, bone and ligament healing — but those effects may look very different among rodents compared to humans. Also, the studies don’t assess what the negative aspects could be, so they’re not telling the whole story.”[1] Human studies were “a handful,” with “essentially no studies demonstrating significant clinical benefits for musculoskeletal conditions”; the few that looked positive, Kremen said, “were done very poorly.”[1]

Two clarifications. MK-677 is technically not a peptide but a small-molecule ghrelin-receptor agonist, though it is marketed as one.[2] And these six are not the group on an FDA compounding panel’s July 2026 list (different list, same bottom line).

The six peptides at a glance: marketed claims vs. evidence

The review’s summary table pairs each product’s marketed claims with the evidence, safety concerns and UCLA verdict.[2] “Marketed claims” are what sellers advertise — not what the evidence shows; none of the six is FDA-approved, and none can be recommended.[1][2]

Peptide by peptide: the evidence in context

BPC-157

Marketed as a fast track to healing for muscle, tendon and ligament injuries, usually as an injectable. The evidence: one human study — a small retrospective case series of people with various knee problems (17 enrolled, 16 assessed), no control group, subjective outcomes.[2] Everything else is animal data, mostly from the group that first isolated the compound. Tewari: “The group that did that study had a financial interest in the compound itself.”[1] Safety concerns: no established human dosing or long-term data, unknown contents, and a theoretical concern about cancer-related pathway activation.[2] UCLA’s verdict: cannot be recommended — it is WADA-prohibited.[2] More: BPC-157 compound page, human trials, reviewed, and STAT and Undark’s investigation of its lead researcher.

TB-500 (thymosin beta-4)

Marketed as a healing and performance peptide — also, in some markets, sold for horses and dogs.[2] The evidence: no peer-reviewed human trials for musculoskeletal use. The human record is disciplinary: the 2016 Essendon AFL case, in which 34 Australian footballers were banned and no performance benefits were documented.[2] Promising animal studies used research-grade thymosin beta-4, which the review stresses is not the same as marketed TB-500 — products vary in sequence and purity.[2] Safety concerns: no long-term human data, unregulated injectable quality, WADA-prohibited.[2] UCLA’s verdict: cannot be recommended.[2] Full file on our TB-500 compound page.

CJC-1295

Marketed as a long-acting growth-hormone-releasing analogue — fewer injections, more growth hormone, better recovery and body composition.[2] The evidence: one phase 1 safety study in 56 healthy adults that collected no performance, body-composition or musculoskeletal data. No human musculoskeletal trials exist.[2] Safety concerns: injection-site reactions in 70% of participants; headache, diarrhea and flushing; unknown long-term effects of overriding natural growth-hormone secretion; a long doping detection window.[2] UCLA’s verdict: cannot be recommended.[2] No dedicated compound page yet — see all peptide compound profiles.

MK-677 (ibutamoren)

Marketed as the no-needle oral growth-hormone secretagogue for muscle and recovery. The evidence: the strongest of the six, and it still falls short: five level-1 randomized trials, all in narrow populations (older adults, hip-fracture and postmenopausal-osteoporosis patients), showing roughly 1.1 kg of lean mass, no strength or functional gains, no fracture-risk reduction, and no athletic or post-surgical data.[2] Safety concerns: the review’s starkest. One hip-fracture trial was stopped early over congestive heart failure — about 6.5% of the treatment group versus about 1.6% on placebo. “They stopped the trial because of a higher rate of congestive heart failure in one of the groups,” Kremen said.[1][2] The review also flags impaired insulin sensitivity and intense hunger.[2] UCLA’s verdict: cannot be recommended, given the potential cardiovascular and metabolic risks.[2]

Ipamorelin

Marketed as a “cleaner” growth-hormone secretagogue — selective stimulation with less hormonal collateral.[2] The evidence: nothing clinical. Ipamorelin is absent from human musculoskeletal trials; the only positive signals are preliminary rodent bone studies.[2] Safety concerns: no long-term human data, the usual growth-hormone-excess risks, and a short half-life requiring frequent injections.[2] UCLA’s verdict: cannot be recommended.[2] See all peptide compound profiles.

GHK-Cu (copper peptide)

Marketed as a wound-healing, collagen-building copper peptide — a skincare staple now increasingly sold as an injectable for musculoskeletal recovery. The evidence: no peer-reviewed human trials for musculoskeletal use; human evidence is confined to topical dermatology, and the musculoskeletal data are one rat ACL-reconstruction study whose transient benefit was gone by 12 weeks.[2] Safety concerns: no established safety profile for injectable use; the same purity and contamination risks as other unregulated products. GHK-Cu was not on the WADA list at the time of the review, a status that may evolve.[2] UCLA’s verdict: cannot be recommended for musculoskeletal use.[2] See our GHK-Cu compound page.

Why the evidence is thin: animal data, weak human studies, and conflicts of interest

Human studies were few, and even the strongest — MK-677’s five randomized trials — sat in older, non-athletic populations with no functional benefit.[2]

Then there is the question of what is in the vial. The review cites a 2017 JAMA analysis of unregulated SARM products — only 52% contained their listed ingredient, 39% contained other unapproved drugs, 25% undeclared substances.[2] Kremen: “Some tests show they contain dangerous substances, like arsenic or lead.”[1] Many products are made outside the U.S., he says, arrive labeled “Not for use in humans,” and are re-mixed by compounding pharmacies.[1] Tewari describes the sales pitch: “gray market peptides” on social media, sold “for research purposes only” to dodge liability.[1] We’ve documented the consequences in contaminated peptides and liver failure and dose inaccuracy in black-market vials. The markers of a mislabelled vial are set out in how counterfeit peptide products are identified.

What this means for athletes and buyers

None of the six is FDA-approved for any use, and the review concludes that peptide supplements “should not currently be recommended as a replacement or adjunct for existing orthopaedic standard of care.”[2] For athletes, five of the six were WADA-prohibited as of the review — BPC-157, TB-500, CJC-1295, MK-677 and ipamorelin — so use carries doping risk, not just health risk (GHK-Cu was not listed at the time of writing).[2] For buyers, “research purposes only” is a legal dodge, not a safety assurance — the same label the FDA has been challenging in warning letters to online peptide sellers. The FDA enforcement timeline, peptide safety FAQ and compounding pharmacy checklist map the regulatory picture; nothing here is medical advice.

The bottom line from UCLA Health

Kremen’s bottom line, in full: “The bottom line is there is little to no evidence these peptide supplements work. And you don’t know what’s in them, so why take the risk? This is very much a situation where the marketing is well ahead of the science. My advice would be to wait until scientists study their effects in a rigorous fashion.”[1] His context: a seemingly healthy rotator-cuff patient whose cardiac output was so low his surgery had to move to a hospital — he admitted to taking peptides. “I can’t really say causality, but it’s certainly a concern,” Kremen said.[1]

His alternative for the goals these products target is deliberately unglamorous: “There are no mysteries in how to appropriately optimize overall performance: sleep, nutrition, strength and aerobic training. These are the building blocks of any successful athlete.”[1]

Frequently asked questions

Are peptides safe?

Some peptide drugs are FDA-approved with strong evidence, but the six unapproved peptides UCLA Health reviewed in 2026 — BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu — “cannot be recommended.” More than two-thirds of the studies the UCLA team analyzed were animal studies, and human evidence for musculoskeletal recovery is weak or absent.[1][2]

Are peptide supplements safe?

Oral collagen-type peptide supplements are a different category from the injectable peptides sold online for recovery and anti-aging. UCLA Health’s September 2026 review of six popular injectables found little evidence of benefit, unknown contents, and safety concerns — including an MK-677 trial stopped early over congestive heart failure.[1][2]

Do peptides work?

It depends which peptide. FDA-approved peptide drugs — insulin, GLP-1 medications — have clear evidence for their approved uses. For the six peptides UCLA Health reviewed in 2026, the review says the evidence “is just not there”: mostly animal studies, a handful of poorly done human studies, and no demonstrated musculoskeletal benefit.[1][2]

What did UCLA Health find about BPC-157?

UCLA Health’s 2026 review found no controlled human trials of BPC-157. The only human study was a small retrospective case series (17 enrolled, uncontrolled); the rest is animal data, most from the single group that isolated the compound. Verdict: “cannot be recommended” — no established dosing, no long-term safety data, WADA-prohibited as of the review.[1][2]

What are the six peptides UCLA Health reviewed?

BPC-157, TB-500 (thymosin beta-4), CJC-1295, MK-677 (ibutamoren), ipamorelin and GHK-Cu (copper peptide). UCLA Health’s September 2026 review found all six “cannot be recommended” for musculoskeletal recovery based on current evidence.[1][2]

Is TB-500 safe?

No peer-reviewed human trials of TB-500 for musculoskeletal use exist, so its long-term safety is unknown. UCLA Health’s 2026 review notes that animal data come from the related protein thymosin beta-4, not marketed TB-500; that the only human history is the 2016 Essendon doping ban, with no documented benefits; and that TB-500 is WADA-prohibited. Verdict: cannot be recommended.[1][2]

Sources

[1] UCLA Health / UCLA Newsroom, Mary-Rose Abraham: With peptide supplements, marketing outpaces the medicine — Q&A with Dr. Thomas J. Kremen Jr. and Kushagra Tewari (published Sept 2, 2026; syndicated Sept 3, 2026 via Medical Xpress)

[2] Tewari, Liu, Im, Hamad, Petrigliano, Cheung, Kremen: Peptide Supplements and Their Therapeutic Applications in Sports Medicine, The American Journal of Sports Medicine (online Aug 11, 2026), DOI 10.1177/03635465261464420

[3] PubMed record: PMID 42578445

[4] UCLA Health newsroom mirror: With peptide supplements, marketing outpaces the medicine

Nothing in this article is medical advice. PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.